{"id":31385,"date":"2026-03-04T00:19:56","date_gmt":"2026-03-04T05:19:56","guid":{"rendered":"https:\/\/tvdelmarva.com\/wp\/chinese-biotech-company-strikes-major-deal-with-belgian-pharmaceutical-giant\/"},"modified":"2026-03-04T00:19:56","modified_gmt":"2026-03-04T05:19:56","slug":"chinese-biotech-company-strikes-major-deal-with-belgian-pharmaceutical-giant","status":"publish","type":"post","link":"https:\/\/tvdelmarva.com\/wp\/chinese-biotech-company-strikes-major-deal-with-belgian-pharmaceutical-giant\/","title":{"rendered":"Chinese Biotech Company Strikes Major Deal with Belgian Pharmaceutical Giant"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n

A Chinese biotechnology company announced Wednesday that it has struck a major licensing deal with Belgian pharmaceutical giant UCB for an experimental treatment targeting autoimmune conditions, with the agreement potentially worth more than $1.1 billion.<\/p>

Antengene Corporation revealed that UCB will pay $60 million immediately and could provide additional payments exceeding $1.1 billion if specific development goals are achieved for the experimental drug ATG-201.<\/p>

In a company statement posted online, Antengene highlighted that the partnership demonstrates the “unique” capabilities of its drug development platform. Following the announcement, the company’s Hong Kong stock shares climbed approximately 6% during Wednesday morning trading.<\/p>

The experimental medication ATG-201 is designed to treat autoimmune conditions related to B-cells. Antengene intends to file for clinical trial approval in both Australia and China during the opening quarter of 2026, and once initial phase I testing concludes, UCB will assume responsibility for continued development.<\/p>

The licensing arrangement grants UCB global rights to develop, produce, and market ATG-201, along with access to related manufacturing processes. Beyond the initial $60 million payment, Antengene stands to receive additional compensation tied to “certain conditions,” development achievements, and commercial success markers, plus ongoing royalty payments based on future sales revenue.<\/p>","protected":false},"excerpt":{"rendered":"

A Chinese biotechnology firm has secured a significant licensing agreement worth potentially over $1 billion for an experimental autoimmune disease treatment. The partnership with Belgium-based UCB includes $60 million upfront with additional milestone payments.<\/p>\n","protected":false},"author":4,"featured_media":31384,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[834],"tags":[],"class_list":["post-31385","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1772601594607.png?fit=1920%2C1080&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pbtNqq-8ad","jetpack-related-posts":[{"id":41987,"url":"https:\/\/tvdelmarva.com\/wp\/belgian-pharma-giant-ucb-plans-2b-georgia-manufacturing-facility\/","url_meta":{"origin":31385,"position":0},"title":"Belgian Pharma Giant UCB Plans $2B Georgia Manufacturing Facility","author":"Admin","date":"March 24, 2026","format":false,"excerpt":"Belgium-based pharmaceutical company UCB has announced plans for a massive $2 billion drug manufacturing facility in suburban Atlanta. The new plant will create approximately 330 jobs and serve as a cornerstone for the company's expanded U.S. market presence.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774391856429.jpg?fit=1000%2C666&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774391856429.jpg?fit=1000%2C666&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774391856429.jpg?fit=1000%2C666&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/03\/news-1774391856429.jpg?fit=1000%2C666&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":61128,"url":"https:\/\/tvdelmarva.com\/wp\/belgium-drug-company-acquires-california-biotech-firm-for-2-2-billion\/","url_meta":{"origin":31385,"position":1},"title":"Belgium Drug Company Acquires California Biotech Firm for $2.2 Billion","author":"Admin","date":"May 3, 2026","format":false,"excerpt":"Belgian pharmaceutical company UCB announced Sunday it will acquire California-based Candid Therapeutics in a deal valued at up to $2.2 billion. The acquisition targets Candid's autoimmune disease treatment development programs.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1777832547142.png?fit=1200%2C675&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":64663,"url":"https:\/\/tvdelmarva.com\/wp\/british-pharmaceutical-giant-partners-with-chinese-company-for-hepatitis-b-drug\/","url_meta":{"origin":31385,"position":2},"title":"British Pharmaceutical Giant Partners with Chinese Company for Hepatitis B Drug","author":"Admin","date":"May 11, 2026","format":false,"excerpt":"British drugmaker GSK announced a new partnership with Hong Kong-based Sino Biopharmaceutical to bring its experimental hepatitis B treatment to mainland China. The collaboration involves GSK's second major deal with a Chinese pharmaceutical company, following a previous $500 million agreement.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1778484191446.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":26083,"url":"https:\/\/tvdelmarva.com\/wp\/pfizer-partners-with-chinese-company-for-new-diabetes-drug-worth-up-to-495m\/","url_meta":{"origin":31385,"position":3},"title":"Pfizer Partners with Chinese Company for New Diabetes Drug Worth Up to $495M","author":"Admin","date":"February 23, 2026","format":false,"excerpt":"Pharmaceutical giant Pfizer has struck a licensing deal with Chinese biotech firm Sciwind Biosciences for a new type 2 diabetes medication called ecnoglutide. The agreement could be worth up to $495 million if certain development and sales targets are achieved.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/02\/news-1771906604274.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":73474,"url":"https:\/\/tvdelmarva.com\/wp\/pfizer-partners-with-chinese-biotech-in-10-5b-cancer-drug-development-deal\/","url_meta":{"origin":31385,"position":4},"title":"Pfizer Partners with Chinese Biotech in $10.5B Cancer Drug Development Deal","author":"Admin","date":"May 28, 2026","format":false,"excerpt":"Pharmaceutical giant Pfizer has entered into a massive collaboration agreement with Chinese biotech company Innovent Biologics to develop a dozen experimental cancer treatments. The partnership includes an immediate $650 million payment and could reach $10.5 billion total in milestone payments.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/05\/news-1780014128420.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":54865,"url":"https:\/\/tvdelmarva.com\/wp\/biogen-secures-china-drug-rights-in-massive-850m-partnership-deal\/","url_meta":{"origin":31385,"position":5},"title":"Biogen Secures China Drug Rights in Massive $850M Partnership Deal","author":"Admin","date":"April 20, 2026","format":false,"excerpt":"Massachusetts-based pharmaceutical company Biogen has struck a major agreement with Chinese biotech firm TJ Biopharma to obtain exclusive rights to market an experimental immune disease treatment in Greater China. The deal could be worth up to $850 million and gives Biogen global control over the promising kidney disease drug felzartamab.","rel":"","context":"In "Business"","block_context":{"text":"Business","link":"https:\/\/tvdelmarva.com\/wp\/category\/business\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/tvdelmarva.com\/wp\/wp-content\/uploads\/2026\/04\/news-1776692197164.jpg?fit=450%2C300&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"jetpack_sharing_enabled":true,"jetpack_likes_enabled":true,"_links":{"self":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/31385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/comments?post=31385"}],"version-history":[{"count":0,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/posts\/31385\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media\/31384"}],"wp:attachment":[{"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/media?parent=31385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/categories?post=31385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tvdelmarva.com\/wp\/wp-json\/wp\/v2\/tags?post=31385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}